Financhill
Sell
28

PEPG Quote, Financials, Valuation and Earnings

Last price:
$2.17
Seasonality move :
-0.65%
Day range:
$2.29 - $2.46
52-week range:
$1.16 - $19.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.65x
Volume:
336.3K
Avg. volume:
5.6M
1-year change:
-84.78%
Market cap:
$76.8M
Revenue:
--
EPS (TTM):
-$2.84

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PEPG
PepGen
-- -$0.72 -- -19.05% $12.20
CPRX
Catalyst Pharmaceuticals
$134.2M $0.55 33.42% 186.84% $33.33
EWTX
Edgewise Therapeutics
-- -$0.42 -- -27.65% $47.13
RGNX
Regenxbio
$23.7M -$1.08 500.31% -68.12% $32.92
SRPT
Sarepta Therapeutics
$631M $2.06 67.9% 370.14% $178.55
VRTX
Vertex Pharmaceuticals
$2.8B $4.02 5.83% 2.33% $496.78
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PEPG
PepGen
$2.35 $12.20 $76.8M -- $0.00 0% --
CPRX
Catalyst Pharmaceuticals
$21.81 $33.33 $2.6B 16.65x $0.00 0% 5.54x
EWTX
Edgewise Therapeutics
$26.43 $47.13 $2.5B -- $0.00 0% --
RGNX
Regenxbio
$7.00 $32.92 $350.6M -- $0.00 0% 4.16x
SRPT
Sarepta Therapeutics
$101.35 $178.55 $9.8B 44.45x $0.00 0% 5.94x
VRTX
Vertex Pharmaceuticals
$513.76 $496.78 $131.9B 26.10x $0.00 0% 12.09x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PEPG
PepGen
-- -2.752 -- --
CPRX
Catalyst Pharmaceuticals
-- 0.693 -- 4.83x
EWTX
Edgewise Therapeutics
-- 0.930 -- --
RGNX
Regenxbio
-- 3.452 -- 2.48x
SRPT
Sarepta Therapeutics
42.67% 1.259 9.65% 2.74x
VRTX
Vertex Pharmaceuticals
-- 1.364 -- 2.17x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PEPG
PepGen
-- -$24.3M -- -- -- -$19.7M
CPRX
Catalyst Pharmaceuticals
$120.2M $62.8M 27.81% 27.81% 44.31% $70.8M
EWTX
Edgewise Therapeutics
-- -$45.5M -- -- -- -$27.2M
RGNX
Regenxbio
$14.9M -$51.4M -70.45% -70.45% -196.89% -$32.7M
SRPT
Sarepta Therapeutics
$526.1M $161.7M 10.04% 20.83% 26.76% $54M
VRTX
Vertex Pharmaceuticals
$2.5B $1.1B -3.23% -3.23% 39.12% $492M

PepGen vs. Competitors

  • Which has Higher Returns PEPG or CPRX?

    Catalyst Pharmaceuticals has a net margin of -- compared to PepGen's net margin of 39.44%. PepGen's return on equity of -- beat Catalyst Pharmaceuticals's return on equity of 27.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    PEPG
    PepGen
    -- -$0.68 --
    CPRX
    Catalyst Pharmaceuticals
    84.74% $0.44 $727.6M
  • What do Analysts Say About PEPG or CPRX?

    PepGen has a consensus price target of $12.20, signalling upside risk potential of 419.15%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $33.33 which suggests that it could grow by 52.84%. Given that PepGen has higher upside potential than Catalyst Pharmaceuticals, analysts believe PepGen is more attractive than Catalyst Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    PEPG
    PepGen
    3 0 0
    CPRX
    Catalyst Pharmaceuticals
    7 0 0
  • Is PEPG or CPRX More Risky?

    PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.836, suggesting its less volatile than the S&P 500 by 16.449%.

  • Which is a Better Dividend Stock PEPG or CPRX?

    PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PEPG or CPRX?

    PepGen quarterly revenues are --, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.8M. PepGen's net income of -$22.2M is lower than Catalyst Pharmaceuticals's net income of $55.9M. Notably, PepGen's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 16.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus 5.54x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PEPG
    PepGen
    -- -- -- -$22.2M
    CPRX
    Catalyst Pharmaceuticals
    5.54x 16.65x $141.8M $55.9M
  • Which has Higher Returns PEPG or EWTX?

    Edgewise Therapeutics has a net margin of -- compared to PepGen's net margin of --. PepGen's return on equity of -- beat Edgewise Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PEPG
    PepGen
    -- -$0.68 --
    EWTX
    Edgewise Therapeutics
    -- -$0.42 --
  • What do Analysts Say About PEPG or EWTX?

    PepGen has a consensus price target of $12.20, signalling upside risk potential of 419.15%. On the other hand Edgewise Therapeutics has an analysts' consensus of $47.13 which suggests that it could grow by 78.3%. Given that PepGen has higher upside potential than Edgewise Therapeutics, analysts believe PepGen is more attractive than Edgewise Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PEPG
    PepGen
    3 0 0
    EWTX
    Edgewise Therapeutics
    4 1 0
  • Is PEPG or EWTX More Risky?

    PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock PEPG or EWTX?

    PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PEPG or EWTX?

    PepGen quarterly revenues are --, which are smaller than Edgewise Therapeutics quarterly revenues of --. PepGen's net income of -$22.2M is higher than Edgewise Therapeutics's net income of -$39.7M. Notably, PepGen's price-to-earnings ratio is -- while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PEPG
    PepGen
    -- -- -- -$22.2M
    EWTX
    Edgewise Therapeutics
    -- -- -- -$39.7M
  • Which has Higher Returns PEPG or RGNX?

    Regenxbio has a net margin of -- compared to PepGen's net margin of -241.28%. PepGen's return on equity of -- beat Regenxbio's return on equity of -70.45%.

    Company Gross Margin Earnings Per Share Invested Capital
    PEPG
    PepGen
    -- -$0.68 --
    RGNX
    Regenxbio
    70.22% -$1.01 $259.7M
  • What do Analysts Say About PEPG or RGNX?

    PepGen has a consensus price target of $12.20, signalling upside risk potential of 419.15%. On the other hand Regenxbio has an analysts' consensus of $32.92 which suggests that it could grow by 370.24%. Given that PepGen has higher upside potential than Regenxbio, analysts believe PepGen is more attractive than Regenxbio.

    Company Buy Ratings Hold Ratings Sell Ratings
    PEPG
    PepGen
    3 0 0
    RGNX
    Regenxbio
    6 1 0
  • Is PEPG or RGNX More Risky?

    PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regenxbio has a beta of 1.354, suggesting its more volatile than the S&P 500 by 35.35%.

  • Which is a Better Dividend Stock PEPG or RGNX?

    PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PEPG or RGNX?

    PepGen quarterly revenues are --, which are smaller than Regenxbio quarterly revenues of $21.2M. PepGen's net income of -$22.2M is higher than Regenxbio's net income of -$51.2M. Notably, PepGen's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus 4.16x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PEPG
    PepGen
    -- -- -- -$22.2M
    RGNX
    Regenxbio
    4.16x -- $21.2M -$51.2M
  • Which has Higher Returns PEPG or SRPT?

    Sarepta Therapeutics has a net margin of -- compared to PepGen's net margin of 24.16%. PepGen's return on equity of -- beat Sarepta Therapeutics's return on equity of 20.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    PEPG
    PepGen
    -- -$0.68 --
    SRPT
    Sarepta Therapeutics
    79.91% $1.50 $2.7B
  • What do Analysts Say About PEPG or SRPT?

    PepGen has a consensus price target of $12.20, signalling upside risk potential of 419.15%. On the other hand Sarepta Therapeutics has an analysts' consensus of $178.55 which suggests that it could grow by 76.17%. Given that PepGen has higher upside potential than Sarepta Therapeutics, analysts believe PepGen is more attractive than Sarepta Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PEPG
    PepGen
    3 0 0
    SRPT
    Sarepta Therapeutics
    12 1 1
  • Is PEPG or SRPT More Risky?

    PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.794, suggesting its less volatile than the S&P 500 by 20.639%.

  • Which is a Better Dividend Stock PEPG or SRPT?

    PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PEPG or SRPT?

    PepGen quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $658.4M. PepGen's net income of -$22.2M is lower than Sarepta Therapeutics's net income of $159M. Notably, PepGen's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 44.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus 5.94x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PEPG
    PepGen
    -- -- -- -$22.2M
    SRPT
    Sarepta Therapeutics
    5.94x 44.45x $658.4M $159M
  • Which has Higher Returns PEPG or VRTX?

    Vertex Pharmaceuticals has a net margin of -- compared to PepGen's net margin of 31.35%. PepGen's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -3.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    PEPG
    PepGen
    -- -$0.68 --
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
  • What do Analysts Say About PEPG or VRTX?

    PepGen has a consensus price target of $12.20, signalling upside risk potential of 419.15%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $496.78 which suggests that it could fall by -3.31%. Given that PepGen has higher upside potential than Vertex Pharmaceuticals, analysts believe PepGen is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    PEPG
    PepGen
    3 0 0
    VRTX
    Vertex Pharmaceuticals
    16 12 1
  • Is PEPG or VRTX More Risky?

    PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

  • Which is a Better Dividend Stock PEPG or VRTX?

    PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PEPG or VRTX?

    PepGen quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. PepGen's net income of -$22.2M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, PepGen's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus 12.09x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PEPG
    PepGen
    -- -- -- -$22.2M
    VRTX
    Vertex Pharmaceuticals
    12.09x 26.10x $2.9B $913M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock